Last reviewed · How we verify

NCT03915171

Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal Cancer

Status unknown NA Last updated 16 April 2019
What this trial tests

NA trial testing Next generation sequencing in Gastrointestinal Cancer in 50 participants. Status unknown.

Timeline
1 March 2019
Primary endpoint
1 December 2019
1 June 2020

Quick facts

Lead sponsorChina Medical University, China
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment50
Start date1 March 2019
Primary completion1 December 2019
Estimated completion1 June 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

China Medical University, China

Who can join

18 and older, any sex, with Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the sensitivity and specificity of NGS in detecting Microsatellite State in blood and to evaluate its potential application in gastrointestinal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Next generation sequencing

Trials testing the same drug.

Other recruiting trials for Gastrointestinal Cancer

Currently open trials in the same condition.

Other China Medical University, China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03915171.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing